Deubiquitinase UCHL5 is elevated and associated with a poor clinical outcome in lung adenocarcinoma (LUAD)

Zhang, Jieru; Xu, Hui; Yang, Xiaomei; Zhao, Yuanjie; Xu, Xinchun; Zhang, Ling; Xuan, Xiaofeng; Ma, Chunping; Qian, Wenxia; Li, Dawei

doi:10.7150/jca.46146



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2020; 11(22):6675-6685. doi:10.7150/jca.46146 This issue Cite

Research Paper

Deubiquitinase UCHL5 is elevated and associated with a poor clinical outcome in lung adenocarcinoma (LUAD)

Jieru Zhang¹, Hui Xu², Xiaomei Yang³, Yuanjie Zhao⁴, Xinchun Xu⁵, Ling Zhang⁶, Xiaofeng Xuan¹, Chunping Ma², Wenxia Qian^1✉, Dawei Li^6✉

1. Department of Respiratory & Critical Care Medicine, The Affiliated Zhangjiagang Hospital of Soochow University, 68 Jiyang West Road, Suzhou, 215600, China.
2. Department of Thoracic Surgery, The Affiliated Zhangjiagang Hospital of Soochow University, 68 Jiyang West Road, Suzhou, 215600, China.
3. Department of Emergency, The Affiliated Zhangjiagang Hospital of Soochow University, 68 Jiyang West Road, Suzhou, 215600, China.
4. Department of General Surgery, The Affiliated Zhangjiagang Hospital of Soochow University, 68 Jiyang West Road, Suzhou, 215600, China.
5. Department of Ultrasound, The Affiliated Zhangjiagang Hospital of Soochow University, 68 Jiyang West Road, Suzhou, 215600, China.
6. Center for Translational Medicine, The Affiliated Zhangjiagang Hospital of Soochow University, 68 Jiyang West Road, Suzhou, 215600, China.

Citation:

Zhang J, Xu H, Yang X, Zhao Y, Xu X, Zhang L, Xuan X, Ma C, Qian W, Li D. Deubiquitinase UCHL5 is elevated and associated with a poor clinical outcome in lung adenocarcinoma (LUAD). J Cancer 2020; 11(22):6675-6685. doi:10.7150/jca.46146. https://www.jcancer.org/v11p6675.htm

Other styles

Abstract

Lung cancer is one of the most common malignant tumors in the world, with a high rate of malignancy and mortality. Seeking new biomarkers and potential drug targets is urgent for effective treatment of the disease. Deubiquitinase UCHL5/UCH37, as an important component of the 26S proteasome, plays critical roles in ubiquitinated substrate degradation. Although previous studies have shown that UCHL5 promotes tumorigenesis, its role in lung cancer remains largely unknown. In this study, we evaluated the expression and clinical significance of UCHL5 in non-small cell lung cancer (NSCLC). The results demonstrated that the UCHL5 expression level was significantly upregulated in NSCLC tissues compared with the adjacent noncancerous tissues. The level of UCHL5 was associated with tumor size, lymph node invasion, TNM stage and malignant tumor history in patients with lung adenocarcinoma (LUAD). Importantly, high UCHL5 expression predicted a poor overall survival (OS) and a poor disease-free survival (DFS) in patients with LUAD. Univariate regression analysis showed that tumor size, lymph node invasion, TNM stage and UCHL5 expression were associated with OS and DFS in patients with LUAD. The multivariate analysis indicated that the UCHL5 expression level was an independent prognostic factor for OS (HR=1.171, 95% CI=1.052-1.303) and DFS (HR=1.143, 95% CI=1.031-1.267) in these patients. UCHL5 knockdown in LUAD cells significantly inhibited cell proliferation and reduced the expression of key cell cycle proteins. These findings indicate that UCHL5 may serve as a potential prognostic marker and a new therapeutic target for patients with LUAD.

Keywords: Deubiquitinase, UCHL5/UCH37, Lung adenocarcinoma, Prognosis, Cell cycle proteins

Citation styles

APA

Zhang, J., Xu, H., Yang, X., Zhao, Y., Xu, X., Zhang, L., Xuan, X., Ma, C., Qian, W., Li, D. (2020). Deubiquitinase UCHL5 is elevated and associated with a poor clinical outcome in lung adenocarcinoma (LUAD). Journal of Cancer, 11(22), 6675-6685. https://doi.org/10.7150/jca.46146.

ACS

Zhang, J.; Xu, H.; Yang, X.; Zhao, Y.; Xu, X.; Zhang, L.; Xuan, X.; Ma, C.; Qian, W.; Li, D. Deubiquitinase UCHL5 is elevated and associated with a poor clinical outcome in lung adenocarcinoma (LUAD). J. Cancer 2020, 11 (22), 6675-6685. DOI: 10.7150/jca.46146.

NLM

CSE

Zhang J, Xu H, Yang X, Zhao Y, Xu X, Zhang L, Xuan X, Ma C, Qian W, Li D. 2020. Deubiquitinase UCHL5 is elevated and associated with a poor clinical outcome in lung adenocarcinoma (LUAD). J Cancer. 11(22):6675-6685.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.